Table 2.
Treatment related outcomes.
| Parameters | N, % |
|---|---|
| Response* | |
| Platelet < 600 (x109/L) at 8 weeks | 32/64 (50.0) |
| Platelet reduction ≥ 50% at 8 weeks | 12/64 (18.8) |
| Platelet normalization (≤ 400 x 109/L) at 8 weeks | 13/64 (20.3) |
| Platelet reduction ≥ 50% at 12 months | 24/55 (43.6) |
| Platelet normalization (≤ 400 x 109/L) at 12 months | 22/55 (40.0) |
| Additional cytoreductive agents use | |
| Hydroxyurea | 14/69 (20.3) |
| 250mg | 3 |
| 500mg | 8 |
| 1000mg | 1 |
| 1500mg | 2 |
| Thromboembolic events, patients** | |
| Cerebral infarction (major arterial thrombosis) | 3 |
| Angina pectoris (minor arterial event) | 1 |
| Bleeding events, patients* | |
| GI bleeding (major bleeding event) | 1 |
| Ecchymosis (minor bleeding event) | 2 |
| Epistaxis (minor bleeding event) | 3 |
| Intracranial hemorrhage (major bleeding event) | 1 |
*Response was calculated from patients stayed on anagrelide treatment regardless of compliance.
**According to predefined criteria (19).